Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News

BARD1 Life Sciences Appoints New CSO

• BARD1 appoints eminent medical researcher Dr Greg Rice as Chief Scientific Officer (CSO) to accelerate the commercial development of its diagnostic tests
• Dr Rice has extensive commercial and academic experience and expertise in biomarker discovery, IP, diagnostics development, quality and regulatory compliance and a track record in developing and commercialising diagnostic tests
• Dr Peter French transitions to a consulting role as Strategic Technology Advisor continuing to support the Company’s R&D programs

Melbourne, Australia, 16 September 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce the appointment of world-leading medical researcher Dr Gregory Rice PhD as Chief Scientific Officer (CSO), effective 20 September 2021.

Dr Rice will lead the Company’s Research and Development (R&D) programs with responsibility for providing scientific leadership, planning R&D strategies, implementing best practice and advancing its diagnostic development programs to achieve value-generating clinical and commercial milestones.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.